Table 3.
Managements and clinical outcomes of COVID‐19 patients
| Characteristic | All patients (n = 304) | Myocardial injury | p value | |
|---|---|---|---|---|
| With (n = 96) | Without (n = 208) | |||
| Managements, n (%) | ||||
| Oxygen inhalation | 206 (67.8) | 85 (88.5) | 121 (58.2) | <.001 |
| Noninvasive ventilation | 62 (20.4) | 35 (36.5) | 27 (13.0) | <.001 |
| Invasive mechanical ventilation | 31 (10.2) | 20 (20.8) | 11 (5.3) | <.001 |
| Immunoglobulin | 122 (40.1) | 23 (24.0) | 99 (47.6) | <.001 |
| Antiviral | 304 (100) | 96 (100) | 208 (100) | ‐ |
| Antibiotic | 118 (38.8) | 65 (67.7) | 53 (25.5) | <.001 |
| Glucocorticoids | 142 (46.7) | 44 (45.8) | 98 (47.1) | .835 |
| Hemoperfusion | 20 (6.6) | 12 (12.5) | 8 (3.8) | .005 |
| Plasmapheresis | 8 (2.6) | 5 (5.2) | 3 (1.4) | .114 |
| Clinical outcomes, n (%) | ||||
| Death | 88 (27.3) | 61 (63.5) | 27 (13.0) | .005 |
| In hospital | 83 (28.9) | 11 (11.5) | 72 (34.6) | |
| Discharge | 133 (43.8) | 24 (25.0) | 109 (52.4) | |
Note: p values are calculated by Student's t test, Mann–Whitney U test, or χ 2 test as appropriate. p values less than 0.05 was statistical significant (Boldface).